Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2023-11-26 |
<Library xmlns="http://hl7.org/fhir">
<id value="179632"/>
<meta>
<versionId value="4"/>
<lastUpdated value="2023-12-15T13:02:51.862Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Library 179632</b></p><a name="179632"> </a><a name="hc179632"> </a><a name="179632-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 4; Last updated: 2023-12-15 13:02:51+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-systematic-review-excluded-studies.html">SystematicReviewExcludedStudies</a></p></div><h2>Participants</h2><table class="grid"><tr><td>Author</td><td>Brian S. Alper</td></tr></table><h2>Related Artifacts</h2><table class="grid"><tr><td>Derived From</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr></table></div>
</text>
<url value="https://fevir.net/resources/Library/179632"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179632"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<system value="urn:ietf:rfc:3986"/>
<value value="urn:oid:2.16.840.1.113883.4.642.40.44.28.2"/>
</identifier>
<version value="2.0.0-ballot"/>
<title
value="SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
<status value="active"/>
<experimental value="false"/>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/library-type"/>
<code value="asset-collection"/>
<display value="Asset Collection"/>
</coding>
</type>
<subjectReference>🔗
<reference value="Group/179619"/>
<type value="Group"/>
<display
value="SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"/>
</subjectReference>
<date value="2023-11-26T18:15:27.442Z"/>
<publisher value="HL7 International / Clinical Decision Support"/>
<contact>
<name value="HL7 International / Clinical Decision Support"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/dss"/>
</telecom>
</contact>
<description value="11 excluded studies"/>
<useContext>
<code>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence-communication"/>
<display value="Evidence Communication"/>
</code>
<valueCodeableConcept>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="SystematicReviewExcludedStudies"/>
<display value="SystematicReviewExcludedStudies"/>
</coding>
</valueCodeableConcept>
</useContext>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
<author>
<name value="Brian S. Alper"/>
</author>
<relatedArtifact>
<type value="derived-from"/>
<resourceReference>🔗
<reference value="Citation/179613"/>
<type value="Citation"/>
<display
value="27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Different comparison (ADT versus ADT plus estramustine)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179628"/>
<type value="Citation"/>
<display
value="14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text
value="Different comparison (ADT versus ADT plus chemotherapy without docetaxel)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179631"/>
<type value="Citation"/>
<display
value="19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179627"/>
<type value="Citation"/>
<display
value="19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179626"/>
<type value="Citation"/>
<display
value="22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Different comparison (ADT versus ADT plus radiotherapy)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179625"/>
<type value="Citation"/>
<display
value="22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Nonrandomized"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179629"/>
<type value="Citation"/>
<display
value="23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Neoadjuvant treatment"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179624"/>
<type value="Citation"/>
<display
value="24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Nonrandomized"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179622"/>
<type value="Citation"/>
<display
value="26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="High-risk localized prostate cancer"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179621"/>
<type value="Citation"/>
<display
value="26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text
value="Locally advanced or metastatic (without metastatic subgroup analysis)"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179630"/>
<type value="Citation"/>
<display
value="26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer."/>
</resourceReference>
</relatedArtifact>
<relatedArtifact>
<type value="contains"/>
<classifier>
<text value="Nonrandomized"/>
</classifier>
<resourceReference>🔗
<reference value="Citation/179623"/>
<type value="Citation"/>
<display
value="23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer."/>
</resourceReference>
</relatedArtifact>
</Library>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change